SEC Filing Summary: Prima BioMed Ltd (Form 6-K)
Business Context and Reporting Period
This Form 6-K was filed by Prima BioMed Ltd, a foreign private issuer, on October 10, 2013. The registrant is headquartered in Sydney, Australia, and files annual reports on Form 20-F. The filing serves to report a specific corporate governance event rather than periodic financial results.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a notice of a change in director's interest and does not contain financial statements or performance data.
Material Changes
The material change disclosed in this filing is the submission of a "Change of Director's Interest Notice" (Exhibit 99.1). No financial or operational changes relative to a prior period are detailed in this specific report.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or discussion of contingencies. The document is strictly a regulatory notification regarding a director's interest.
Key Facts for Investor Verification
- Event: A director of Prima BioMed Ltd has reported a change in their interest in the company's securities.
- Document Reference: The specific details of the interest change are located in Exhibit 99.1 (Appendix 3Y).
- Financial Data: Investors should refer to the company's most recent Form 20-F or quarterly reports for financial performance, as this Form 6-K contains no financial metrics.
- Signatory: The report was signed by Matthew Lehman, Chief Executive Officer.